How will vaccine developers be confident that they will not see their expected market return taken by generic copies?
Second and subsequent products entering the market guaranteed by the commitment must demonstrate that they are superior to existing vaccines, and not merely generic copies. This is similar to arrangements under the Orphan Drug Act. (It is also worth noting that it is harder to make generic copies of vaccines than for drugs, for various technical and regulatory reasons.
